2017/04/29 by Marie-Eve Lalonde, Marie‐Eve Lalonde, Yves Durocher
Biochemistry, Genetics and Molecular Biology · #Transgenic Plants and Applications #Viral Infectious Diseases and Gene Expression in Insects #Virus-based gene therapy research
paper · doi:10.1016/j.jbiotec.2017.04.028
openalex publication_date 2017/04/29 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
Over the last years, the biopharmaceutical industry has significantly turned its biologics production towards mammalian cell expression systems. The presence of glycosylation machineries within these systems, and the fact that monoclonal antibodies represent today the vast majority of new therapeutic candidates, has largely influenced this new direction. Recombinant glycoproteins, including monoclonal antibodies, have shown different biological properties based on their glycan profiles. Thus, the industry has developed cell engineering strategies not only to improve cell's specific productivity, but also to adapt their glycosylation profiles for increased therapeutic activity. Additionally, the advance of "omics" technologies has recently given rise to new possibilities in improving these expression platforms and will significantly help developing new strategies, in particular for CHO (Chinese Hamster Ovary) cells.